Baillie Gifford & Co’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-40,378
| Closed | -$912K | – | 282 |
|
|
2024
Q3 | $912K | Sell |
40,378
-2,701,775
| -99% | -$61M | ﹤0.01% | 256 |
|
|
2024
Q2 | $53.3M | Sell |
2,742,153
-4,682,613
| -63% | -$91.1M | 0.04% | 138 |
|
|
2024
Q1 | $279M | Sell |
7,424,766
-495,210
| -6% | -$18.6M | 0.22% | 85 |
|
|
2023
Q4 | $443M | Sell |
7,919,976
-420,922
| -5% | -$23.6M | 0.35% | 65 |
|
|
2023
Q3 | $344M | Sell |
8,340,898
-163,349
| -2% | -$6.74M | 0.31% | 72 |
|
|
2023
Q2 | $475M | Sell |
8,504,247
-249,740
| -3% | -$13.9M | 0.4% | 58 |
|
|
2023
Q1 | $488M | Buy |
8,753,987
+151,752
| +2% | +$8.47M | 0.44% | 58 |
|
|
2022
Q4 | $313M | Buy |
8,602,235
+158,847
| +2% | +$5.79M | 0.33% | 71 |
|
|
2022
Q3 | $240M | Buy |
8,443,388
+64,417
| +0.8% | +$1.83M | 0.25% | 83 |
|
|
2022
Q2 | $379M | Buy |
8,378,971
+1,023,207
| +14% | +$46.3M | 0.39% | 69 |
|
|
2022
Q1 | $560M | Buy |
7,355,764
+477,387
| +7% | +$36.3M | 0.39% | 65 |
|
|
2021
Q4 | $1.02B | Buy |
6,878,377
+1,335,752
| +24% | +$199M | 0.56% | 50 |
|
|
2021
Q3 | $807M | Buy |
5,542,625
+511,629
| +10% | +$74.5M | 0.42% | 61 |
|
|
2021
Q2 | $985M | Buy |
5,030,996
+3,634,870
| +260% | +$712M | 0.48% | 52 |
|
|
2021
Q1 | $253M | Buy |
1,396,126
+621,106
| +80% | +$112M | 0.14% | 114 |
|
|
2020
Q4 | $110M | Buy |
775,020
+263,573
| +52% | +$37.3M | 0.06% | 128 |
|
|
2020
Q3 | $63.8M | Buy |
511,447
+507,150
| +11,802% | +$63.2M | 0.04% | 134 |
|
|
2020
Q2 | $384K | Buy |
4,297
+2,708
| +170% | +$242K | ﹤0.01% | 229 |
|
|
2020
Q1 | $99K | Buy |
+1,589
| New | +$99K | ﹤0.01% | 218 |
|